Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861328 | 1.00 | REN (0.38) | RENACP1MEN1KMT2ACHRM3 | |
| SCHEMBL1859948 | 1.00 | REN (0.38) | RENACP1MEN1KMT2ACHRM3 | |
| SCHEMBL1861330 | 1.00 | REN (0.38) | RENACP1MEN1KMT2ACHRM3 | |
| SCHEMBL3597925 | 0.86 | REN (0.40) | RENMEN1KMT2ACHRM3 | |
| SCHEMBL1867383 | 0.86 | REN (0.40) | RENMEN1KMT2ACHRM3 | |
| SCHEMBL1867384 | 0.86 | REN (0.40) | RENMEN1KMT2ACHRM3 | |
| SCHEMBL3597921 | 0.86 | REN (0.40) | RENMEN1KMT2ACHRM3 | |
| SCHEMBL1864217 | 0.85 | CYP2D6 (0.45) | MEN1KMT2ACHRM3SLC6A2 | |
| SCHEMBL1860521 | 0.85 | CYP2D6 (0.45) | MEN1KMT2ACHRM3SLC6A2 | |
| SCHEMBL1864215 | 0.85 | CYP2D6 (0.45) | MEN1KMT2ACHRM3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | REN 298/4885ACP1 391/4885MEN1 2596/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | REN 298/4885ACP1 391/4885MEN1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.